• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Kancera

Less than 1K followers
Overview
Investor consensus
All
Webcasts
Press releases
ShowingAll content types

Press release16.07.2026, 10.40

Novakand Pharma Provides an Operational Update Regarding Management, Website, and Planned Extraordinary General Meeting

Kancera
Press release25.06.2026, 15.00

Novakand Pharma consolidates forces for the development of orphan drugs against cancer

Kancera
Press release31.03.2026, 08.00

Novakand Pharma to hold Extraordinary General Meeting to decide on future business direction – Comments from the board of directors

Kancera

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release02.03.2026, 07.00

Novakand’s Board of Directors proposes new business direction and relisting to be presented at Extraordinary General Meeting

Kancera
Press release25.02.2026, 16.45

The board evaluates Novakand Pharma’s options after the decision not to execute the planned reverse take over of SVF Vaccines

Kancera
Press release12.02.2026, 17.45

Novakand Pharma applies for Nasdaq’s approval of continued listing of the combined company post a completed reverse takeover with SVF Vaccines

Kancera
Press release06.02.2026, 08.00

Novakand Pharma enters into share purchase agreement with SVF Vaccines regarding a reverse takeover

Kancera
Regulatory press release22.12.2025, 08.00

Novakand Pharma enters Letter of Intent with SVF Vaccines regarding a reverse takeover

Kancera
Regulatory press release21.11.2025, 08.00

Interim Report Third Quarter 2025, July 1 – September 30 Novakand Pharma AB (publ.), org.no. 556806-8851

Kancera
Press release09.10.2025, 09.00

Novakand Pharma provides an update on the ongoing reverse take over process

Kancera
Regulatory press release23.09.2025, 15.00

Peter Selin resigns as CEO of Novakand Pharma in mutual agreement with the board

Kancera
Regulatory press release22.09.2025, 16.00

Kancera AB changes name to Novakand Pharma AB

Kancera
Regulatory press release18.09.2025, 18.00

Kancera initiates process to seek stakeholders for a reverse take over

Kancera
Regulatory press release28.08.2025, 08.00

Interim Report First Quarter 2025, April 1 – June 30 Kancera AB (publ.), org.no. 556806-8851

Kancera
Regulatory press release12.08.2025, 08.00

Kancera terminates letter of intent with Recardio

Kancera
Press release16.06.2025, 08.30

Kancera announces rugocrixan and fosrugocrixan as the International Non-proprietary Names for KAND567 and KAN145

Kancera
Regulatory press release13.06.2025, 08.00

Kancera reports positive top-line results from the KANDOVA study

Kancera
Regulatory press release05.06.2025, 08.00

Kancera reports positive outcome of pre-IND meeting with FDA

Kancera
Press release27.05.2025, 08.39

Redeye: Kancera Q1 - Continued efforts with Recardio

Kancera
Regulatory press release23.05.2025, 08.00

Interim Report First Quarter 2025, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

Kancera